bdp 12 has been researched along with Parkinson Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumbarger, P; Bleakman, D; Gates, M; Hicks, CA; Lodge, D; Murray, TK; Nisenbaum, ES; O'Neill, MJ; Ogden, AM; Robinson, CS; Siuda, E; Skolnick, P; Vandergriff, JL; Ward, MA; Whalley, K; Zimmerman, DM | 1 |
1 other study(ies) available for bdp 12 and Parkinson Disease
| Article | Year |
|---|---|
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amides; Animals; Biphenyl Compounds; Cells, Cultured; Corpus Striatum; Dioxoles; Disease Models, Animal; Excitatory Amino Acid Agonists; GAP-43 Protein; Hippocampus; Humans; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Piperidines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Substantia Nigra | 2003 |